Steven Wise
Endocrinology, Diabetes & Metabolism · Dothan, ALNPI 1659327468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 181 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$644
- Amgen$388
- AstraZeneca$332
- Bayer$232
- Lilly USA, LLC$197
- Corcept Therapeutics$169
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,12599%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $644 |
| Amgen | 21 | $388 |
| AstraZeneca(2 entities) | 17 | $332 |
| Bayer | 14 | $232 |
| Lilly USA, LLC | 13 | $197 |
| Corcept Therapeutics | 8 | $169 |
| Xeris Pharmaceuticals, Inc. | 5 | $104 |
| Boehringer Ingelheim | 5 | $93 |
| Dexcom, Inc. | 6 | $85 |
| Medtronic(2 entities) | 3 | $73 |
| Ultragenyx Pharmaceutical Inc. | 3 | $68 |
| Johnson & Johnson | 4 | $67 |
| IBSA Pharma Inc. | 3 | $58 |
| Abbott | 3 | $47 |
| Tandem Diabetes Care, Inc. | 3 | $47 |
| Amryt Pharma Holdings Ltd | 2 | $41 |
| Radius Health, Inc. | 2 | $40 |
| Merck | 3 | $39 |
| Nevro Corp. | 2 | $37 |
| Insulet Corporation | 1 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Cequr Corporation | 1 | $33 |
| Shire North American Group Inc | 2 | $29 |
| AbbVie | 2 | $26 |
| GRT US Holding, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Vivus LLC | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
How this compares
$3,148 in reported general payments places this provider in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Other endocrinology, diabetes & metabolism in Dothan
- Bruce TrippeDothan$68K
- John StoneDothan$3K
- Brian WiethopDothan$2K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.